L. fermentum

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: digestion immunity inflammation

Research Overview

Across the abstracts, Limosilactobacillus fermentum (formerly Lactobacillus fermentum) research is most developed in three areas: (i) mechanistic and formulation-oriented work on probiotic traits (e.g., biofilm formation and biofilm-inspired encapsulation approaches aimed at improving survival through stressors such as gastric acidity and processing), (ii) antimicrobial and colonization-related functions in the urogenital/vaginal niche (co-aggregation with pathogens, epithelial adhesion, biofilm behavior in combinations, and activity of cell-free supernatants), and (iii) immunometabolic and antioxidant effects relevant to chronic low-grade inflammation (including metabolic syndrome/overweight outcomes, gut barrier and inflammatory signaling in vitro, and broader reviews of antioxidant phenotypes across strains). A smaller but emerging mechanistic theme is the characterization of L. fermentum-derived extracellular vesicles (EVs) and their protein cargo as potential mediators of host–microbe interactions and as inputs for functional food development.

The strongest evidence in these abstracts supports two conclusions. First, L. fermentum strains can exhibit robust in vitro antagonism against a range of bacterial urogenital pathogens via secreted factors (heat-stable activity with partial sensitivity to enzymatic treatment, consistent with organic acids and/or proteinaceous antimicrobials depending on strain), alongside adhesion/co-aggregation traits that are plausibly relevant to colonization; however, activity appears strain- and target-dependent (e.g., weaker effects against some enterococci and limited interference with Candida spp.). Second, there is direct human clinical evidence—albeit for a specific multi-strain L. fermentum mixture—that supplementation over ~3 months can modestly improve adiposity-related and liver steatosis–related parameters in abdominal overweight, with additional benefits when combined with a prebiotic (synbiotic) for some endpoints. Complementary in vitro data support plausible mechanisms (tight-junction upregulation, reduced inflammatory mediator expression, antioxidant capacity), but these are demonstrated for particular strains and models rather than as a class effect.

Key gaps are largely about translation, specificity, and mechanism. Many findings are strain-specific, yet comparative genomics/phenotyping and standardized reporting (dose, viability, formulation, and endpoints) remain insufficient to generalize across L. fermentum. Vaginal applications require controlled in vivo studies to confirm colonization dynamics, clinical efficacy against defined urogenital syndromes, and safety in relevant populations. For metabolic and endocrine indications (e.g., overweight/metabolic syndrome and multi-strain interventions that include L. fermentum in PCOS), more trials are needed that isolate the contribution of L. fermentum, establish durability of effects, and link outcomes to mechanistic biomarkers (microbiome shifts, barrier function, inflammatory tone, uric acid metabolism where relevant). Finally, EV biology and biofilm-inspired “fourth-generation” delivery concepts are promising but remain early-stage; causal pathways, active cargos, and clinically meaningful advantages over conventional formulations require rigorous validation.

1. What conditions has L. fermentum been studied for?

  • Overweight / metabolic syndrome traits (humans): Studied in a double-blind, randomized, placebo-controlled trial in adults with abdominal overweight, using a mixture of L. fermentum strains (K7-Lb1, K8-Lb1, K11-Lb3), with or without acacia gum (synbiotic).

  • Polycystic ovary syndrome (PCOS) (humans): Studied as one component of a multi-strain probiotic plus dietary/lifestyle modification for 6 months (included L. fermentum UBLF-31 among other strains).

  • Urogenital/vaginal infections (preclinical/in vitro): Vaginal isolate L. fermentum 18A-TV evaluated for interference with urogenital pathogens (adhesion, co-aggregation, biofilm-related properties) and antimicrobial activity of cell-free supernatants against multidrug-resistant bacteria and Candida spp.

  • Inflammation, gut barrier dysfunction, and osteoporosis-related markers (in vitro/preclinical model): L. fermentum SRK414 evaluated in LPS-stimulated inflammation models and a dexamethasone-induced osteoporosis model, including tight junction gene expression and bone metabolism-related markers.

  • Oxidative stress and related chronic disease phenotypes (mixed evidence base): A review summarizes in vitro, animal experiments, and “some clinical trials” where various L. fermentum strains modulated host antioxidant systems and improved systemic disease phenotypes.

  • Cardiometabolic/inflammatory/oxidative stress parameters (preclinical safety + background claims): A novel fruit by-product-derived mixture (L. fermentum 139, 263, 296) is described as being “associated with improvements” in cardiometabolic, inflammatory, and oxidative stress parameters; the cited abstract focuses on genotoxicity and 13-week toxicity in rats.

  • Hyperuricemia (HUA) (background rationale): One abstract frames HUA and notes probiotics may help via gut microbiota regulation, but does not provide specific L. fermentum outcomes in the excerpt provided.

  • Formulation/viability and delivery technology (not a disease): Studied in the context of probiotic biofilms and “fourth generation probiotics” (biofilm-inspired encapsulation) and in simulated gastrointestinal conditions with nutraceutical combinations (e.g., L. fermentum 296 with quercetin/resveratrol).

2. Does it work in treating those conditions? Summarize the evidence.

  • Overweight / metabolic syndrome traits: In a 3-month double-blind RCT (n=180) in abdominal overweight individuals, the L. fermentum probiotic mixture produced statistically significant improvements vs placebo in multiple anthropometric and imaging outcomes. Reported between-group differences favored probiotics for:

    • Body fat mass change (primary outcome): probiotic group −0.61 ± 1.94 kg vs placebo +0.13 ± 1.64 kg (p=0.039).

    • Body weight (p=0.012), BMI (p=0.011), waist circumference (p=0.03), waist-to-height ratio (p=0.033).

    • Visceral adipose tissue (sonographic SAD) (p<0.001) and liver steatosis grade (LSG) (p<0.001).

    • Synbiotic arm (probiotic + acacia gum) improved SAD (p=0.002), LSG (p<0.001), and constipation score (p=0.009) vs placebo.

    Interpretation: This is direct human evidence that a specific L. fermentum strain mixture can improve several overweight-associated parameters over 3 months. It does not prove all L. fermentum strains or products will do the same (strain- and formulation-specific effects are likely).

  • PCOS: A 6-month randomized trial (n=104) found that a multi-strain probiotic (including L. fermentum UBLF-31 plus several other Lactobacillus/Bifidobacterium strains and fructo-oligosaccharides), combined with dietary and lifestyle modifications, improved:

    • Menstrual cycle regularity (p=0.023).

    • Total testosterone (p=0.043).

    • Waist circumference (p=0.030) and waist-to-hip ratio (p=0.027).

    • Menstrual domain of quality of life (p=0.034).

    Interpretation: Evidence supports benefit of the combination intervention, but the effect cannot be attributed specifically to L. fermentum because multiple strains, a prebiotic (FOS), and lifestyle changes were used.

  • Urogenital/vaginal infections: Evidence in the provided abstract is in vitro. Vaginal isolates including L. fermentum 18A-TV showed strong co-aggregation with urogenital pathogens, adhesion to HeLa cells, and (in combination) biofilm formation. Cell-free supernatants were strongly bactericidal against many multidrug-resistant urogenital pathogens, with notable exceptions (no strong effect reported for E. faecium and E. faecalis), and limited impact on Candida spp. The authors explicitly note that in vivo studies are needed.

    Interpretation: Promising mechanistic/preclinical support, but not proof of clinical treatment efficacy.

  • Inflammation/gut barrier and osteoporosis-related markers: L. fermentum SRK414 showed high antioxidant capacity and, along with L. plantarum A41, upregulated tight junction mRNA and inhibited inflammatory mediators in an LPS-stimulated model; it also regulated bone metabolism-related markers relevant to bone homeostasis/osteoblast differentiation.

    Interpretation: These are preclinical/experimental findings; they support plausibility but do not establish clinical efficacy for osteoporosis or inflammatory diseases.

  • Oxidative stress-related outcomes: A review states that in vitro, animal studies, and some clinical trials show various L. fermentum strains can beneficially modulate host antioxidant systems and improve systemic disease phenotypes. Specific trial outcomes are not detailed in the provided excerpt.

    Interpretation: Suggestive but not confirmatory from the excerpt alone; strength depends on the quality and consistency of the underlying studies.

  • Hyperuricemia: The excerpt provides rationale but no direct results for L. fermentum in HUA.

3. What health benefits does it have?

  • Improved body composition and metabolic risk markers (human RCT evidence for specific strains): The L. fermentum strain mixture trial reported improvements in body fat mass, weight, BMI, waist measures, visceral adiposity (SAD), and liver steatosis grade (LSG) over 3 months vs placebo.

  • Potential constipation improvement (human RCT evidence for synbiotic): The synbiotic arm (probiotic + acacia gum) improved constipation score vs placebo (p=0.009), suggesting a possible GI benefit when combined with a fermentable fiber.

  • Antimicrobial activity against urogenital pathogens (in vitro): Vaginal L. fermentum 18A-TV (with other Lactobacilli) showed strong interference with multidrug-resistant urogenital bacteria via co-aggregation/adhesion and bactericidal activity of cell-free supernatants; activity was heat-stable and partially reduced by enzymatic treatment, consistent with organic acids and/or proteinaceous antimicrobials contributing.

  • Barrier support and anti-inflammatory signaling (preclinical): L. fermentum SRK414 increased tight junction mRNA expression and inhibited inflammatory mediators in an LPS-stimulated model, consistent with improved gut barrier function and reduced inflammatory signaling (preclinical evidence).

  • Antioxidant effects (mixed evidence base): A review summarizes that multiple L. fermentum strains can modulate host antioxidant systems and improve oxidative-stress-related phenotypes in experimental studies and some clinical trials (details not provided in the excerpt).

  • Product stability/delivery potential (formulation benefit): Biofilm-based probiotic forms may increase resistance to temperature, gastric pH, and mechanical forces compared with planktonic forms, and biofilm-inspired encapsulation (“double coated capsules”) is described as enabling “fourth generation probiotics.” This is a delivery/viability advantage rather than a direct health outcome.

  • Mechanistic plausibility via extracellular vesicles (EVs): L. fermentum-derived EVs contain proteins linked to catalytic activity, gluconeogenesis, cell wall organization, and glycolysis; motif enrichment found serine-rich motifs. This supports mechanistic exploration for functional foods but does not itself demonstrate clinical benefit.

4. Does it have any downsides or side effects?

  • Clinical tolerability (limited but reassuring in provided abstracts): In the PCOS trial of a multi-strain probiotic (including L. fermentum UBLF-31) taken for 6 months, the authors report no adverse events related to the study.

  • Preclinical safety signals (reassuring for a specific mixture): A safety evaluation of a novel L. fermentum mixture (strains 139, 263, 296) reported no increase in micronuclei frequency in a rat micronucleus assay up to the highest tested dose (excerpt truncated) and included a 13-week repeated-dose toxicity study (details not provided in the excerpt). This supports lack of genotoxicity in that model.

  • Limitations/unknowns: Many benefits described are strain-specific and/or based on in vitro or animal models; side effects can vary by population (e.g., immunocompromised individuals) and product quality, but such risks are not addressed in the provided abstracts. Also, antimicrobial effects were not universal in vitro (e.g., limited activity against E. faecium, E. faecalis, and poor co-aggregation with Candida spp.), which is not a “side effect” but indicates limits to expected efficacy.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

No pharmacogenomic or gene-variant-specific effects are described in the provided abstracts for L. fermentum. The excerpts discuss strain properties (e.g., antimicrobial metabolites, EV protein cargo, antioxidant/anti-inflammatory effects) and clinical outcomes, but they do not link responses or risks to human genetic polymorphisms.

Practical implication: Based on these abstracts alone, there is insufficient evidence to recommend L. fermentum specifically for (or against) people with particular genetic variants.

References

  1. Biofilm Forming Lactobacillus: New Challenges for the Development of Probiotics.
    María José Salas-Jara, Alejandra Ilabaca, Marco Vega, Apolinaria García (2016) - Microorganisms
  2. Antimicrobial properties of Lactobacillus cell-free supernatants against multidrug-resistant urogenital pathogens.
    Marina Scillato, Ambra Spitale, Gino Mongelli, Grete Francesca Privitera, Katia Mangano, Antonio Cianci, Stefania Stefani, Maria Santagati (2021) - MicrobiologyOpen
  3. Proteomic characterization of extracellular vesicles derived from lactic acid bacteria.
    Bao-Hong Lee, You-Zuo Chen, Tang-Long Shen, Tzu-Ming Pan, Wei-Hsuan Hsu (2023) - Food chemistry
  4. Lactobacillus fermentum F40-4 ameliorates hyperuricemia by modulating the gut microbiota and alleviating inflammation in mice.
    Jiayuan Cao, Ting Wang, Yisuo Liu, Wei Zhou, Haining Hao, Qiqi Liu, Boxing Yin, Huaxi Yi (2023) - Food & function
  5. Effect of a Probiotic and a Synbiotic on Body Fat Mass, Body Weight and Traits of Metabolic Syndrome in Individuals with Abdominal Overweight: A Human, Double-Blind, Randomised, Controlled Clinical Study
    Christiane Laue, Ekaterina Papazova, Angelika Pannenbeckers, Jürgen Schrezenmeir (2023)
  6. Anti-inflammatory and Anti-osteoporotic Potential of Lactobacillus plantarum A41 and L. fermentum SRK414 as Probiotics.
    Chul Sang Lee, Sae Hun Kim (2020) - Probiotics and antimicrobial proteins
  7. Limosilactobacillus fermentum, Current Evidence on the Antioxidant Properties and Opportunities to be Exploited as a Probiotic Microorganism.
    Luciana Caroline Paulino do Nascimento, Diego Cabral Lacerda, Diorginis José Soares Ferreira, Evandro Leite de Souza, José Luiz de Brito Alves (2022) - Probiotics and antimicrobial proteins
  8. Efficacy of multi-strain probiotic along with dietary and lifestyle modifications on polycystic ovary syndrome: a randomised, double-blind placebo-controlled study.
    Ishwarpreet Kaur, Vanita Suri, Naresh Sachdeva, Satya Vati Rana, Bikas Medhi, Nancy Sahni, Jayesh Ahire, Amarjeet Singh (2022) - European journal of nutrition
  9. Limosilactobacillus fermentum Strains as Novel Probiotic Candidates to Promote Host Health Benefits and Development of Biotherapeutics: A Comprehensive Review.
    Micaelle Oliveira de Luna Freire, José Patrocínio Ribeiro Cruz Neto, Deborah Emanuelle de Albuquerque Lemos, Thatyane Mariano Rodrigues de Albuquerque, Estefânia Fernandes Garcia, Evandro Leite de Souza, José Luiz de Brito Alves (2024) - Probiotics and antimicrobial proteins
  10. Safety Evaluation of a Novel Potentially Probiotic Limosilactobacillus fermentum in Rats.
    José Patrocínio Ribeiro Cruz Neto, Alison Macário de Oliveira, Kataryne Árabe Rimá de Oliveira, Karoliny Brito Sampaio, Maria Letícia da Veiga Dutra, Micaelle Oliveira de Luna Freire, Evandro Leite de Souza, José Luiz de Brito Alves (2024) - Probiotics and antimicrobial proteins
  11. An Overview of the Use and Applications of
    Maria Paula Racines, Maria Nicole Solis, Miroslava Anna Šefcová, Róbert Herich, Marco Larrea-Álvarez, Viera Revajová (2023) - Microorganisms
  12. Significance of
    Dharmisthaben Patel, Amar Sakure, Dikshita Lodha, Bethsheba Basaiawmoit, Ruchika Maurya, Sujit Das, Mahendra Bishnoi, Kanthi Kiran Kondepudi, Subrota Hati (2023) - Journal of the American Nutrition Association
  13. Effects of Simulated Gastrointestinal Conditions on Combined Potentially Probiotic Limosilactobacillus fermentum 296, Quercetin, and/or Resveratrol as Bioactive Components of Novel Nutraceuticals.
    Karoliny Brito Sampaio, José Luiz de Brito Alves, Yuri Mangueira do Nascimento, Josean Fechine Tavares, Marcelo Sobral da Silva, Davi Dos Santos Nascimento, Noádia Priscila de Araújo Rodrigues, Mariana Costa Monteiro, Estefânia Fernandes Garcia, Evandro Leite de Souza (2024) - Probiotics and antimicrobial proteins
  14. Lactobacillus sp. improved microbiota and metabolite profiles of aging rats.
    Yan-Yan Hor, Lee-Ching Lew, Mohamad Hafis Jaafar, Amy Sie-Yik Lau, Jia-Sin Ong, Tamotsu Kato, Yumiko Nakanishi, Ghows Azzam, Azali Azlan, Hiroshi Ohno, Min-Tze Liong (2019) - Pharmacological research
  15. Survival and stability of Lactobacillus fermentum and Wickerhamomyces anomalus strains upon lyophilisation with different cryoprotectant agents.
    Raquel Facco Stefanello, Elizabeth Harumi Nabeshima, Beatriz Thie Iamanaka, Aline Ludwig, Leadir Lucy Martins Fries, Angélica Olivier Bernardi, Marina Venturini Copetti (2019) - Food research international (Ottawa, Ont.)
  16. Effect of Lactobacillus fermentum TKSN041 on improving streptozotocin-induced type 2 diabetes in rats.
    Xianrong Zhou, Guan-Sheng Shang, Qian Tan, Qin He, Xiaoyu Tan, Kun-Young Park, Xin Zhao (2021) - Food & function
  17. Alleviating effect of
    Yishu Chen, Kangdi Zheng, Yang Leng, Zhao Zhang, Xiaoling Li, Xiaoyan Li, Huajun Ou, Muhao Wen, Feng Qiu, Huajun Yu (2025) - Frontiers in nutrition
  18. Preventive Effect of
    Xingyao Long, Haibo Wu, Yujing Zhou, Yunxiao Wan, Xuemei Kan, Jianjun Gong, Xin Zhao (2022) - Frontiers in nutrition
  19. The anticancer effect of potential probiotic L. fermentum and L. plantarum in combination with 5-fluorouracil on colorectal cancer cells.
    Sanaz Salek, Elham Moazamian, Afshin Mohammadi Bardbori, Seyedeh Azra Shamsdin (2024) - World journal of microbiology & biotechnology
  20. Probiotic Lactobacillus fermentum KU200060 isolated from watery kimchi and its application in probiotic yogurt for oral health.
    Sung-Min Lim, Na-Kyoung Lee, Kee-Tae Kim, Hyun-Dong Paik (2020) - Microbial pathogenesis


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!